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Abstract
In adult mammals, after optic nerve injury, retinal ganglion cells (RGCs) do not regenerate their axons and most of them die
by apoptosis within a few days. Recently, several strategies that activate neuronal intracellular pathways were proposed to
prevent such degenerative processes. The rho-related small GTPase Rac1 is part of a complex, still not fully understood,
intracellular signaling network, mediating in neurons many effects, including axon growth and cell survival. However, its role
in neuronal survival and regeneration in vivo has not yet been properly investigated. To address this point we intravitreally
injected selective cell-penetrating Rac1 mutants after optic nerve crush and studied the effect on RGC survival and axonal
regeneration. We injected two well-characterized L61 constitutively active Tat-Rac1 fusion protein mutants, in which a
second F37A or Y40C mutation confers selectivity in downstream signaling pathways. Results showed that, 15 days after
crush, both mutants were able to improve survival and to prevent dendrite degeneration, while the one harboring the F37A
mutation also improved axonal regeneration. The treatment with F37A mutant for one month did not improve the axonal
elongation respect to 15 days. Furthermore, we found an increase of Pak1 T212 phosphorylation and ERK1/2 expression in
RGCs after F37A treatment, whereas ERK1/2 was more activated in glial cells after Y40C administration. Our data suggest
that the selective activation of distinct Rac1-dependent pathways could represent a therapeutic strategy to counteract
neuronal degenerative processes in the retina.
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Introduction
In adult mammalian central nervous system (CNS) neurons fail
to regenerate after injury. Many approaches have been tried with
the aim of promoting neuronal survival and reactivation of an
axonal growth program that is normally shut down at the end of
development [1,2]. Although the intracellular signaling underlying
neuronal survival and axonal regeneration are still partially
understood, increasing evidence has shown that stimulation of
intrinsic pathways could be an effective strategy [2–5].
Rac1 is a Rho-related small GTPase that regulates cytoskeletal
dynamics and plays a critical role in neuronal development, axon
growth and cell survival [6]. The constitutively active (CA) form of
Rac1 was able to promote axonal growth through an inhibitory
environment both in vitro [7] and in vivo [8] and to promote
survival in vitro [9,10]. However, Kusano and coworkers obtained
regeneration by using a dominant negative (DN) Rac1 on a model
of sciatic nerve injury [11]. Indeed, a critical point is that Rac1 is a
signaling network hub and can potentially interact with several
downstream effectors [12]; hence, its pure CA and DN forms
could influence simultaneously many downstream, and likely
concurrent, signaling pathways, leading to contrasting effects.
In order to investigate the role of Rac1 in neuronal survival and
regeneration in vivo and to limit the inherent uncertainty due to the
multitude of possible interactions, we coupled the pure constitu-
tively activating L61 mutation to a second mutation in the effector
domain (F37A or Y40C) in order to block the specific interaction
of Rac1 with a pool of downstream effectors. It was shown that
after F37A point mutation Rac1 retains the ability to interact with
PAK and to influence JNK activation, whereas for the Y40C
mutant the above-mentioned interactions are blocked, at least
in vitro [13,14]. We fused the mutants with a Tat Trojan sequence
to mediate the cell internalization. We used the well known model
of optic nerve injury to study the role of Rac1 in neuronal survival
and regeneration, injecting intravitreally (ivit) the two double
mutants after crush. These mutants have been previously
characterized [13–15], but to our knowledge, they have never
been used in vivo in the CNS.
Our results showed that selective activation of Rac1-dependent
signaling pathways improved cell survival and axonal regeneration
until 15 days post-injury. Moreover, after Rac1L61F37A treat-
ment we observed an increase of p21-activated kinase 1 (Pak1)
T212 phosphorylation in RGCs together with extracellular signal-
regulated kinase 1 and 2 (ERK1/2) upregulation. On the other
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hand the L61Y40C increased ERK1/2 activation in radial glia.
Our study clarifies the role of Rac1 as a pro-survival signaling
molecule in neurons in vivo and supports the possibility of using the




Mice were maintained under standard environmental condi-
tions (temperature, humidity, 12 h/12 h light/dark cycle, with
water and food ad libitum) under veterinarian assistance. Animals
handling and surgery were performed following a protocol which
Figure 1. Rac1 selective activation increased RGC survival until 15 days after optic nerve crush in YFPH mice. Representative confocal
images of flat mounted normal (A), and injured retinas after treatments with 2 injections (at day 0 and day 2 post lesion) of either vehicle (B) or
Rac1WT (C), or Rac1L61F37A (D), or Rac1L61Y40C (E), or the DN Rac1-N17 (F). Retinas were excised at 15dpl and stained in order to detect RGCs (bIII
tubulin, red), and YFP (anti-GFP, green). The dramatic neuronal loss observed in the vehicle-treated mice (B) was reduced in mice treated with either
Rac1L61F37A (D) or Rac1L61Y40C (E). Scale bar 50 mm. Mutants were tested for different experimental protocols, whose scheme is shown in (G). YFPH
mouse optic nerves were crushed at day 0 and, after one or more injections of Rac1 mutants, WT or vehicle, retinas were dissected 15 or 30 days post
crush in order to investigate RGCs survival. After staining for bIII tubulin, flat mounted retinas were imaged and processed for the evaluation of
survival as described in methods. (H-I) Quantification of RGC survival after optic nerve crush and Rac1 selective activation at 15 and 30 days post
lesion in YFPH mice. The results at 15 dpl are shown in H, where both CA mutants were able to improve survival. Only the L61F37A exerted a dose
dependent effect, whereas the DN N17 mutant decreased survival. At 30 dpl (I) the survival of Rac1 L61F37A treated mice decreased at the level of
controls, even after repetitive injections, indicating that the mutant was unable to sustain survival at 30 days. Data are mean 6SEM, N is in brackets.
*p,0,05; #p,0.01 versus the controls (one way ANOVA followed by LSD post hoc test).
doi:10.1371/journal.pone.0064350.g001
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received approval by the Animal Care and Use Committee of the
University of Verona (CIRSAL), and authorization by the Italian
Ministry of Health, in strict adherence to the European
Communities Council directives (86/609/EEC), minimizing the
number of animals used and avoiding their suffering.
The 2 transgenic models used were purchased from the Jackson
laboratory (Bar Harbor, ME, USA): B6.Cg-Tg(Thy1- YFPH)2Jrs/
2J (referred to as YFPH) and B6.CBA-Tg(Thy1-Brainbow1.0)-
LLich/J (referred to as Brainbow 1.0 ) mice. YFPH mice were
genotyped by PCR. Some immunofluorescence experiments were
performed on C57BL6/J mice to avoid the presence of
endogenous fluorochromes. We used the YFPH mouse line, in
which a few RGCs constitutively express the yellow fluorescent
protein (YFP) under the thy1 promoter [16], to evaluate the
survival and the whole cell morphology of RGCs. Since in YFPH
mice the number of fluorescent axons in the optic nerve is very
small and variable among mice, we used the Brainbow mice to
assess regeneration [17]. In these mice the YFP is expressed only
after Cre-dependent recombination that we obtained by an
Adeno-Associated Virus carrying the green fluorescent protein-
fused Cre recombinase (AAV-Cre-GFP). If we perform the AAV-
Cre-GFP injection around the day of crush, we will achieve
recombination and expression of YFP only in the axons of
surviving neurons (for more details see Fig. S1).
Tat-protein Fusion Production
The penetration of mutant proteins in cells was achieved by a
Tat Trojan sequence, an approach that has been previously used
[18]. We constructed a series of specific Tat fusion protein
expression vectors based on pRSETa-b-c vectors (Life Technol-
ogies, Carlsbad, CA, USA), designed for high-level protein
expression and purification on nickel columns upon expression
in Escherichia coli. A detailed description of Trojan peptides
production is available in the supplementary material of [15]. A
scheme of the recombinant protein mutants with all the mutations
and a complete amino acid sequence are available in Fig. S2.
Optic Nerve Crush and Intravitreal Injection Procedure
Animals were anesthetized with trimbromethanol (TBE, ip dose
of 0,4 g/kg body weight) and the left optic nerve was exposed
intraorbitally. The onset of RGC death depends on the distance of
the injury from the retina [19], so we performed an intraorbital
lesion of optic nerve at a fixed distance of 2 mm from the eye,
applying a pressure with jewelers’ forceps for 10 s [20,21]. The
eyes of experimental and control animals were ivit injected with
mutants or vehicle (PBS): each injection consisted of 1 ml at 5 mM
concentration of Tat-protein. Injections were performed by using
a heat-pulled glass capillary connected to a picospritzer (Parker
Instrumentation, NH, USA), (0.05 ms pulse duration, pressure of
10 psi). Injections were given slowly and the capillary was
maintained in position for additional 10 min to minimize protein
loss through the injection tract. The first injection was done just
after optic nerve crush, and then animals were allowed to recover
in their cage. We performed one or more injections in the
following days according to different schemes of treatment
described in the Fig. 1G. At the end of the experiment, 15 or 30
days post crush, mice were sacrificed by terminal anesthesia and
transcardially perfused with 4% paraformaldehyde in PBS,
pH 7.4. The eyes and optic nerves were removed, postfixed and
processed for immunofluorescence as described below or directly
mounted and studied by using a TCS-SP5 confocal microscope
(Leica-Mycrosystems, Wetzlar, Germany).
In the analysis of regeneration (15 and 30 days post crush),
Brainbow 1.0 mice were also ivit injected with 1 ml of AAV-Cre-
GFP two days before the optic nerve crush in order to allow the
recombination and the expression of YFP in the axons.
At the dissection step, eyes showing lens injury were excluded
from the study, because survival and regeneration of RGCs is
stimulated by crystal lens damage [20]. Since inflammation could
affect survival and regeneration [22], all controls received the
same number of vehicle injections of the experimental mice.
Immunofluorescence
Retinas (whole tissue or 15 mm thick cryosections, depending on
the experiment) were permeabilized with the following solution:
2% Bovine Serum Albumin, 2% Normal Goat Serum, 0,3% of
Triton X-100, in PBS, pH 7.4 for 30 minutes. Then tissues were
incubated 24 h at 4uC with primary antibodies and, after washes,
with the proper secondary Alexa Fluor-conjugated antibodies (Life
Technologies, Carlsbad, CA, USA) for 1 h at RT. Nuclei were
stained by DAPI (Sigma-Aldrich, St Louis, MO, USA). After
mounting, retinas were studied by confocal microscopy.
The following primary antibodies were used: anti-bIII tubulin,
anti-Pak1, anti Phospho-Pak1 (Thr 212), anti-JNK and anti-di
Phospho-JNK (Thr 183 and Tyr 185) were purchased from
Sigma-Aldrich (St Louis, MO, USA), Alexa 488-conjugated anti-
GFP and anti-Histag were purchased from Life Technologies
(Carlsbad, CA, USA), anti-ERK1/2 and anti-Phospho-ERK1/2
(Thr 202 and Tyr 204) were purchased from Cell Signaling,
(Beverly, MA, USA), anti-GFAP (MAB360) was purchased from
Millipore (Billerica, MA, USA).
Confocal Imaging Analysis
Analysis of cell survival. Six confocal stacks of the RGC
layer were acquired from each flat mounted retina after bIII
tubulin staining at 4006 magnification (406 oil immersion
objective, HCX PL APO Lambda blue,1.25 numerical aperture
(NA), Leica Microsystems, Wetzlar, Germany). bIII tubulin was
used as a marker for surviving RGCs as it is an efficient and
reliable method for selective labeling of viable RGCs [23]. Given
that the neuronal density changes with the distance from the optic
disc, we acquired images at two different distances: 3 images from
the medial and 3 from the peripheral retina. A manual count of
RGCs was done on the z-stack. Since the crush was performed
mono-laterally, the mean RGC density of the contralateral eyes
was used as reference for the number of RGCs before crush. The
ratio, expressed as percentage, between the RGC density of the
crushed retina and the reference was referred to as the survival
rate.
Analysis of dendrite morphology. YFPH positive neurons
(10 to 20 neurons per treatment) were acquired by confocal
microscopy at 4006magnification by using the 406oil immersion
objective (1.25 NA). In the YFPH retina RGCs are well separated
between each other. Given the presence of 6 different morpho-
logical types of RGCs in the mouse retina, we focused only on type
4 neurons that are the most resistant to death after crush [24].
Type 4 neurons were recognized on the basis of their distance
from the optic disc (1.8–2 mm). Z-stacks were acquired and the
maximum intensity projections (MIPs) were obtained by using the
LAS-AF software (Leica-Microsystems, Wetzlar, Germany). On
the MIPs the Sholl analysis was performed by using the ImageJ
specific plugin (NIH, Bethesda, MD, USA). In this analysis, after
application of a treshold, a series of concentric circles with
increasing radii were automatically drawn by the software starting
from the center of the cell body that was manually set (5 mm radius
step size; starting radius 10 mm). The program evaluates the
number of dendritic intersections at each value of the radius,
resulting in a main plot (N of intersections against the distance
Rac1 in Cell Survival and Regeneration
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form soma), together with a series of parameters that we used for
the statistical analysis: the maximum number of intersections, the
ramification index and the critical value.
Analysis of regeneration. Brainbow1.0 whole mounted
nerves were acquired at 4006magnification (406 oil immersion
objective, 1.25 NA) by laser scanning microscopy. We acquired
adjacent z-stacks (100 mm of z-thickness) and after mosaic merge
and identification of the crush site, regenerating axons were
manually counted in the images every 100 mm starting from the
crush site. The number of axons was plotted against the distal
nerve length.
Analysis of Pak/ERK/JNK signal intensities. After stain-
ing the retina cryosections, 3 images per retina were randomly
acquired from 3 to 6 mice per treatment at 4006magnification
Figure 2. Rac1 selective activation prevents the dendrite atrophy occurring after crush. Representative confocal maximum projections of
YFPH mouse RGCs 15 days after crush and double injection of either vehicle or CA or DN mutants. A normal RGC is shown for comparison (A). After
Rac1L61F37A and Y40C treatment (D and E respectively) the dendritic atrophy is prevented, whereas the same extent of degeneration was found in
control (B) and after DN treatment (C). The plots relative to the Sholl analysis for the different treatments are shown in F–G: (F) the maximum number
of intersections, the ramification index and the critical value were used for statistical evaluation (10 to 20 neurons per treatment), whereas (G) the N of
intersections against the distance from the soma shows the morphological changes along the whole dendritic tree. Scale bar 20 mm. # p,0,01
versus the control, the L61F37A and the L61Y40C; *p,0,05 versus the indicated group (one way ANOVA followed by LSD post hoc test).
doi:10.1371/journal.pone.0064350.g002
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(406 oil immersion objective, 1.25 NA). In order to compare the
fluorescence intensities coming from different samples, we
performed the staining with the same antibody solutions, on the
same day and we kept constant all the acquisition parameters
during the imaging sessions. On the z-stack a ROI was drawn in
correspondence of the ganglion cell layer and the average intensity
was measured over the entire layer by using the LAS-AF software.
Data were expressed as normalized data on the control value (e. g.
the normal retina).
All images were processed by using the LAS-AF software (Leica-
Mycrosystems, Wetzlar, Germany) and ImageJ (NIH, Bethesda,
MD, USA).
Statistical Analysis
For the analysis of cell survival and dendrite intersections (Sholl
analysis) data were evaluated by ANOVA followed by LSD post
hoc test. For the evaluation of axonal regeneration we counted the
number of axons at different distances from the crush site from
100 to 1000 mm (100 mm bin size). Data were processed for
repeated measure ANOVA followed by LSD post-hoc test, using
the length as within subjects factor and the treatments as between
subjects factor. For the evaluation of differences in the number of
regenerating axons at each length (for instance only at 100 mm) we
used the one way ANOVA followed by LSD post hoc test.
The evaluation of immunofluorescence intensity was done by
ANOVA followed by LSD post-hoc test.
All statistical analyses were performed by SPSS (IBM, New
York, NY, USA) software. An alpha level of 0.05 was considered
as significant.
Results
Rac1 Selective Activation Promoted RGC Survival 15 Days
after Optic Nerve Crush
To unveil the role of Rac1 on neuronal survival in vivo we used
YFPH mouse line in which a few RGCs constitutively express YFP
[16]. We performed an optic nerve crush and injected ivit two CA-
Tat-Rac1 selective double mutants: the L61F37A and the
L61Y40C. As controls, we used vehicle and a Tat-Rac1WT
isoform that can freely cycle between the active and the inactive
state responding to the cell activity. Moreover some mice were
injected with the Tat-Rac1N17 that is the DN Rac1 isoform. All
the experimental and the control treated mice received the same
number of injections and eyes with signs of crystal lens damage
were excluded from this study (see methods).
In preliminary experiments, we tested the effect of different
doses of the Tat-Rac1 mutants on RGC viability in a concentra-
tion range between 5 to 80 mM. We found that 5 to 10 mM gave
the highest RGC viability (data not shown) and thus we decided to
Figure 3. Rac1 selective activation promotes axonal regener-
ation after optic nerve crush in Brainbow mice. In Brainbow mice
the injection of the AAV-Cre-GFP around the day of crush triggers a
genetic recombination that leads to YFP expression (white false color)
only in surviving neurons. We injected either the Tat-Rac1 mutants, WT
or vehicle on the day of crush (day 0) and on day 2 and studied
regeneration 15 days post lesion. A scheme of the treatment is in A.
Nerves were acquired and studied by confocal microscopy. Single
examples of whole mounted nerves after mosaic merge reconstruction
are given in B to E, and are relative to vehicle (B), Rac1WT (C), L61F37A
mutant (D) and L61Y40C mutant (E) double injections. The crush sites of
B, C, D and E are enlarged in F, G, H and I respectively. By comparison of
the panels it is clear that after treatment with L61F37A a higher number
of axons is able to cross the crush site and run distally (D and H). Scale
bars 100 mm.
doi:10.1371/journal.pone.0064350.g003
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use 5 mM in this study. Fig. 1 shows examples of normal (A) and
crushed retinas (B to F), with or without Rac1 mutant treatment:
eyes were injected twice and excised 15 days post-lesion as shown
in the scheme of Fig. 1G (second treatment: 2 inj 15 days). A
relevant neuronal loss was found in controls (B and C), while the
treatment with either the Rac1 L61F37A (D) or the L61Y40C (E)
protected RGCs from death. On the contrary the DN isoform
exacerbated neuronal death.
Fig. 1H and I show the quantification of RCG survival in mice
treated according to the different protocols illustrated in G: i) a
single injection performed the day of the crush (day 0) ii) the
double injections performed at day 0 and day 2 with excision at 15
or iii) at 30 days and iv) the repetitive injection over 30 days.
In controls the 24% of neurons survived at 15 days post lesion
(dpl) but in mice treated with Rac1L61F37A double injection the
percentage increased to 50%. The L61F37A was the most effective
mutant in a dose-dependent fashion. The L61Y40C mutant was
also able to increase survival but at a lower level and without
apparent dose-dependency. On the contrary the N17 mutant
significantly impaired the neuronal survival. Given these results
only the F37A mutant was tested for longer time.
When we look at the plot 1I relative to the two treatments at
30 dpl, we observed that the L61F37A was unable to sustain RGC
survival. Since vehicle treatment resulted in the same survival after
2 or 5 injections, we grouped together the data showing a single
column for controls (n = 8).
These data suggest that Rac1 selective activation is able to
improve RGC survival until 15 dpl.
The retinas receiving double injections and excised at 15 dpl
were processed for the evaluation of dendrite morphology. Fig. 2
shows representative confocal images of class 4 RGCs (Leung
et al., 2011) from the different treatments. The morphology of
neurons was well conserved after Rac1 selective activation (D-E),
while in controls and in N17 treatment it was dramatically altered
(B and C). Results indicate that Rac1 selective activation was able
to prevent the dendrite atrophy naturally occurring after crush.
The Sholl analysis confirmed and supported the differences
observed, revealing a dramatic decrease of complexity of the
dendritic tree after vehicle and DN treatments as compared to
Rac1 selective activation (Fig. 2 F–G). Moreover, since we
observed opposite effects for CA and DN Rac1 isoforms, we can
exclude that the differences on survival and dendritic trophism are
related to the blocking of the GTPase cycling.
Selective Activation of Rac1 Promoted RGCs Axonal
Regeneration Following Crush Injury
In order to study axonal regeneration, we used the Brainbow
1.0 mouse [17], in which the red fluorescent protein (RFP) is
Figure 4. Quantification of axonal regeneration after optic
nerve crush and Rac1 selective activation in Brainbow mice.
Brainbow mouse optic nerves were crushed at day 0 and, after one or
more injections of either Rac1 mutants, WT or vehicle, were dissected at
15 or 30 days post crush in order to investigate regeneration. A scheme
of the different treatments is given in A. Nerves were studied by
confocal microscopy and the results of the regeneration study are
plotted in B, C and D. Only the double injection of L61F37A was able to
increase the average number of axons crossing the crush site per
100 mm of nerve z-section (B) at 15 days post lesion. The number of
regenerating axons is higher than control also after 2 and 5 injections of
L61F37A at 30 dpl. The data at 15 days are confirmed also by the
analysis of length distribution in the entire distal stump (C). The same
analysis at 30 days (D) revealed that, despite after 2 and 5 L61F37A
injections the total number of regenerating neurons are similar, the
repetitive treatment resulted in longer axons. Since we found no
differences between the various vehicle injection protocols of
treatment at 15 and 30 days, we put together the data of the controls
on the same column/curve (n = 6 and 8). Data are mean 6SEM. N is in
brackets. #p,0.01, *p,0.05 by ANOVA (LSD post hoc test).
doi:10.1371/journal.pone.0064350.g004
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basally expressed by all neurons under the thy1 promoter. In this
transgenic line the ivit injection, around the day of crush, of an
AAV-Cre-GFP triggers the expression of yellow and cyan
fluorescent proteins (YFP and CFP) only in the surviving neurons
(see methods and Fig. S1). The RFP gene is concomitantly deleted
in recombining neurons. After the recombination the CFP signal
in the optic nerve was faint respect to the YFP, thus we excluded it
from the analysis and showed only the YFP signal in white false
color (Fig. 3). The recombination occurs in about the 75% of
neurons, so in this model the regeneration is underestimated.
To test whether Rac1 selective activation could improve axonal
regeneration, we injected the virus (day 22) and after 2 days we
performed the crush (day 0) followed by ivit injection of the two
different Tat-Rac1 mutants, with the same protocols of treatment
used for the survival study (see also scheme in Fig. 4A). First we
evaluated the regeneration 15 days post lesion. Fig. 3 shows
examples of confocal images of mice treated with two injections
and excised at 15 dpl (see scheme 3A or 4A second treatment).
Here a higher number of regenerating axons spanning the crush
site were found in L61F37A treated animals (Fig. 3 D and H)
respect to controls (B, C, F and G). After quantification, we found
that double injection of L61F37A significantly increased the
average number of regenerating axons as compared to controls at
15 dpl (Fig. 4B). This data was also confirmed by the analysis of
the length distribution in the distal nerve stump (Fig. 4C).
Conversely, neither the single L61F37A nor the L61Y40C single
and double injections showed any significant effects.
In order to define the effect of long-term treatments of L61F37A
on axonal regeneration, we performed experiments in which
nerves were excised 30 dpl after 2 (on day 0 and 2) or 5 injections
(see scheme in Fig. 4A, 2inj and 5 inj 30 days). As shown in Fig. 5,
after 5 injections of L61F37A many axons were found spanning
the crush site (Fig. 5 C and F). This was not observed neither after
5 vehicle injections (A, D), nor after double injection of mutant
(Fig. 5 B, E).
As shown in the quantification (Fig. 4B 30 days), at 30 dpl more
regenerating axons were found after L61F37A treatments respect
to their control. Moreover, at the same time point, 5 injections
with L61F37A resulted in longer axons with respect to 2 injections
(Fig. 4D). This is important if we consider that the survival rate at
30 dpl is the same in controls and in treated animals (Fig. 1I).
Since we found no differences between the various vehicle
injection protocols of treatment at 15 and 30 dpl, we grouped
together the data of the controls (n = 6 for 15 dpl and 8 for 30 dpl).
Interestingly, when we compared data obtained at 15 and
30 dpl, we found no statistical differences between the double
L61F37A injection at 15 dpl and the 5 injections at 30 dpl,
suggesting that repetitive injections of mutant are unable to
improve regeneration after 15 dpl. On the contrary, we found a
significant decrease in axonal length between the controls at
15 dpl and those at 30 dpl and also between the double injection
of L61F37A at 15 and at 30 dpl (Fig. 4 C vs D). It seems likely that
sustained delivery of L61F37A could prevent further nerve
degeneration.
Our data suggest that Rac1 selective activation may improve
regeneration until 15 days post injury, and that the repetitive
treatment could be able to delay the axonal degeneration.
Injection of Rac1 CA Mutants Increased Pak1
Phosphorylation and ERK1/2 Activation in Different
Retina Cell Types
In order to study the half-life of the Tat-proteins we performed
Histag specific staining (see Fig. S3 and S4) from 2 to 4 days after a
single Tat-protein injection. We observed that after 2 and 3 days
from the injection the mutant protein was still present in the
retina, while the signal was no more detectable at 4 days.
To assess what proteins could be involved in the effect observed
after Rac1L61F37A and Y40C treatment on RGC neurons, we
stained retina cryosections with different antibodies recognizing
either the pan-specific or the phosphorylated form of some of the
most common downstream Rac1 effectors: Pak1, ERK1/2 and the
c-jun N-terminal kinase (JNK). We performed the staining 3 days
after crush and double injection of Tat-conjugated proteins. In this
way, we were quite sure to detect the effect in a period when the
Tat-proteins were still present and not yet degraded by cell/tissue
metabolism. We found an L61F37A-dependent increase of both
total and phospho-ERK1/2 and phospho-Pak1 (T212) in the
RGC layer (Fig. 6 K and L). These increments were specifically in
RGCs as shown by the colocalization with the bIII tubulin (Fig. 6
A–B). We also found an increase of the total ERK1/2 and JNK as
compared to vehicle treatment (Fig. 6K and Fig. S5). However,
since we observed the same pattern for JNK expression in the WT-
treated animal, we concluded that this effect might not be strictly
related to the Rac1 constitutive activation.
As concern the Y40C isoform, the observed colocalization with
the glial fibrillary acidic protein (GFAP) together with the
evaluation of the phospho/pan antibody ratio, indicated that the
Y40C mutant treatment resulted in the activation of ERK1/2
specifically in glial cells (Fig. 6 E-F and K-L) and not in neurons
(Fig. 6 G-H). Although the Histag staining after both mutant
treatments indicates that the Tat-proteins mainly targets RGCs
(we showed only the Histag staining after L61Y40C injection in
Fig. 6 N-O and Fig. S4 but the pattern for the F37A isoform is the
same, data not shown), we found a surprising but specific positivity
for the phospho-ERK1/2 in the radial glia.
In order to confirm the specificity of these effects we injected the
mutants in normal eyes and 48h after single injection we repeated
the staining on the retinas obtaining the same results (see Fig. S6):
after Y40C treatment the level of phospho-ERK1/2 was increased
in non-neuronal cells, whereas after F37A treatment the positivity
for phospho-Pak1 was increased in RGCs.
Our data suggest that different CA isoforms of Rac1 are able to
promote Pak1 phosphorylation and ERK1/2 activation in vivo on
different cell types acting by distinct mechanisms.
Discussion
In this study, we demonstrated that two cell-penetrating fusion
proteins, selectively modulating the signaling activity of the rho
small GTPase Rac1, contrasted the RGC death and stimulated the
axon regrowth in a model of optic nerve injury in vivo. Our data
showed that both Tat-Rac1L61F37A and Tat-Rac1L61Y40C
double mutants, each one capable of modulating distinct arms of
the Rac1-dependent signaling cascade, were able to promote
survival and to prevent dendrite atrophy until 15 days post lesion.
In particular, the L61F37A mutant was the most effective and
Figure 5. Long-term effects on axonal regrowth of Rac1L61F37A treatment in Brainbow mice. Single examples of whole mounted
Brainbow mouse nerves after mosaic merge reconstruction, relative to the 30 dpl treatments described in figure 4A and D. Images shows treatments
with vehicle (A), 2 (B) and 5 (C) L61F37A injections. The crush sites of A, B and C are enlarged in D, E and F respectively. Longer axons were found
distally from the crush site after multiple injections of the Rac1 mutant. Scale bars 100 mm.
doi:10.1371/journal.pone.0064350.g005
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Figure 6. Phosphorylation of Pak1 and upregulation of ERK1/2 after injections of Rac1 mutants. Retina sections were immunostained by
antibodies against the pan-specific and the phosphorylated form of Pak1 (T212), ERK1/2 and JNK. Retinas were dissected and immunostained 3 days
after optic nerve crush and ivit treatment with either vehicle, or Rac1WT, or L61F37A or L61Y40C. Some representative relevant images are shown in
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showed a dose-dependent increase of RGC survival. The DN
isoform of Rac1 induced opposite effects both on survival and on
dendrite morphology, suggesting that the observed effects are not
due to the blocking of the RhoGTPase cycling, as indicated in
some studies [25], but are rather a specific effect of Rac1 activity
modulation. Moreover, we found that the L61F37A mutant was
able to promote regeneration until 15 days post-injury and that
sustained delivery into the eye by repetitive ivit injections was able
to prevent the normal axonal degeneration observed in control
nerves at 30 days after injury.
Finally, by immunostaining we observed ERK1/2 upregulation
and increase of Pak1 T212 phosphorylation in RGCs after
L61F37A mutant treatment. On the other hand after L61Y40C
administration we observed an increase of survival, and contex-
tually an ERK1/2 activation specifically in glial cells, raising the
possibility that the two Rac1 selective mutants act by different
mechanisms. Overall, our study shows that Rac1 is a complex
modulator of neuronal survival, morphology and regeneration
in vivo.
Activation of Rac1 Downstream Interactors Protected
RGCs from Injury-induced Death
To our knowledge, our study is the first demonstrating a direct
correlation between Rac1 activation and improvement of neuro-
nal survival in vivo. To date, only in vitro evidence [9,10] has been
provided, with in vivo data showing indirect and controversial
findings. For example, one study reported that Rac1 activates the
pro-death mixed lineage kinase 3 (MLK3)-JNK kinase signaling
pathway promoting neuronal cell death following cerebral
ischemia [26], while in another study, Rac1 deletion from
germinative zones determined microcephaly [27].
The two mutants used in this work were characterized for the
first time in fibroblasts in 1996 by Lamarche and coworkers [13].
In these constitutively active mutants, the effector domain of Rac1
is mutated in order to limit the number of putative downstream
interactions. It was shown that the L61F37A mutant retained the
ability to activate Pak and indirectly JNK, whereas the L61Y40C
mutant displayed opposite effects, blocking the activation of both
proteins. However the type and number of downstream interac-
tions are strictly related to the specific cell context and to the
model.
Some pathways downstream to Rac1 were found to be
neuroprotective in vitro: a Rac1-dependent Pak/MEK/ERK1/2
signaling was found to be protective against apoptosis in cerebellar
granule neurons [28,29], and recent studies reported that some
neuroprotective agents act by increasing ERK1/2 phosphoryla-
tion in the retina [30–32]. Moreover, in RGCs the tonic activation
of ERK1/2 by overexpression of a constitutively active mitogen-
activated protein kinase kinase 1 (MEK1) mutant was able to
improve survival after optic nerve injury [33].
In our model we observed by immunostaining an increase in
Pak1 T212 phosphorylation in RGCs following L61F37A
treatment. This phosphorylation is specifically targeted by the
p35/Cdk5 association, whose role in neuroprotection was
demonstrated during development and under stress conditions
[34–36]. Moreover Pak1 phosphorylation by Cdk5 was found to
be of critical importance in the complex mechanisms that regulate
axonal growth and cell reaction to toxic stimuli [14,37].
Rac1L61 CA mutant is able to associate to both p35 and Cdk5,
while the F37A mutated Rac1 cannot directly bind the p35,
indicating that Cdk5 might not be a direct downstream effector of
the F37A [14]. Other pathways are likely involved. For example it
has been reported many times that ERK stimulates p35
transcription [34] and we found ERK upregulation in RGCs
after F37A treatment. A more thorough investigation of the
pathways downstream F37A treatment are required and will be
object of further studies possibly on more simple experimental
models.
Following L61Y40C treatment we did not find any Pak1 or
JNK significant alteration, suggesting that the two mutants act by
means of different mechanisms. The L61Y40C mutant deter-
mined a surprising increase of ERK1/2 activation in radial glia.
This result is not easily interpretable since we showed by
immunostaining that the Tat-proteins are mainly localized in
RGCs. However it must be considered that the Tat-trojan peptide
sequence does not act in a cell-selective manner and there is no
reason to assume that the Tat-proteins are internalized by the
RGCs only, especially in consideration of the close proximity of
glial cells to RGCs. Another hypothesis should be that ERK
activation in glial cells might be an indirect effect due to a neuron-
glia cross-talk. This aspect needs to be investigated in further
studies on a more suitable model such as mixed neuron-glia in vitro
cultures.
The improvement of survival obtained by treatment with the
L61Y40C mutant might be related to ERK1/2 activation in glial
cells. In retinal astrocytes it was shown that the stimulation of
ERK1/2 leads to secretion of endogenous CNTF [38]. It will be
interesting to verify, in further studies, the involvement of
neurotrophin secretion as intermediate of the Rac1L61Y40C
mutant action on neuronal survival.
Inflammation has a well known role in RGC survival [20,39],
but it can be excluded that the findings of our study are related to
inflammation processes because the results obtained in control
treated mice, by using both the vehicle alone and a Rac1 WT
isoform are significantly different from those obtained with the
same protocols on experimental mice.
In our experiments at 30 dpl the survival level was the same in
control and in treated eyes, and this temporal limitation of action
has been observed also for many other agents [40]. Indeed recent
studies have shown that the manipulation of a single intracellular
pathway is not sufficient to block the apoptotic process for a long
period [41].
Rac1 is also a complex regulator of dendrite morphology
[42,43] and this was confirmed by our data, showing that Rac1
activation could prevent the dendrite atrophy normally occurring
after injury. In our optic nerve injury model we found, as
A to J, N and O. (A–B) Colocalization of phospho-Pak1 (Pak1-p, red) and bIII tubulin (green) indicates that the L61F37A resulted in Pak1-p increase in
RGCs, confirmed also by the lack of colocalization with GFAP (C–D). (E–F) Colocalization of phospho-ERK (ERK1/2-p, red) and GFAP (green) indicates
that the L61Y40C mutant activated ERK1/2 in retinal glial cells. (G–H) The lack of colocalization between MAP2 (blue) and ERK1/2-p after Y40C
treatment indicates that this protein is not activated in neurons. A control is also shown (I–J) where ERK1/2-p positivity is very low. (N–O) Histag
staining after L61Y40C treatment showed a clear positivity in RGCs, meanwhile the ERK1/2-p positivity pattern was still glial-like. (K) Semi-quantitative
expression of total and phosphorylated level of Pak1, ERK1/2, and JNK measured in correspondence of the ganglion cell layer and normalized on the
signal of the normal eye (n = 9 to 15 confocal stacks from 3 to 6 animals). (L) Ratio between the normalized intensity of phosphorylated and total
forms of Pak1, ERK1/2 and JNK gives an indication about the degree of kinase activity. Scale bar 30 mm. GCL: ganglion cell layer. (M) We hypothesize
that L61F37A effect on survival might be related to the increased expression of ERK1/2 and increased Pak1 phosphorylation in neurons. Meanwhile,
L61Y40C is most likely boosting survival through the activation of ERK1/2 in astrocytes.
doi:10.1371/journal.pone.0064350.g006
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expected, that selective CA and DN isoforms exerted opposite
effects both on neuronal survival and on dendrite morphology,
confirming their value as tool to investigate complex phenomena.
Rac1 Selective Activation Promoted Axonal Regeneration
After optic nerve crush and L61F37A treatment, we found
many axons spanning the crush site and run distally in the optic
nerve stump, suggesting that this mutant was able to allow the
axonal growth through non-permissive environment and to
stimulate the intrinsic regenerative program of neurons.
Our findings are in keeping with the study of Jain and
coworkers, in which a CA Rac1 was able to promote axonal
regeneration in a model of spinal cord injury [8]. Indeed the
pathways activated by our L61F37A mutant and the CA Rac1
used by Jain are likely to be partially overlapping. However,
Kusano and coworkers obtained the same results by using a DN
Rac1 isoform on a model of sciatic nerve injury [11]. The
differences might be related to the different context: peripheral
versus central nervous system.
The L61F37A ability to increase regeneration could be related
to Pak1 T212 phosphorylation. To date data supporting a role for
Pak1 in CNS regeneration in vivo are missing. Pak modulation in
neuroblastoma cells in vitro was found to stimulate axonal growth
through non-permissive environment and in particular its dead-
kinase isoform was found to be very efficient to overcome
inhibition [44]. Moreover Pak1 inhibition by the p35/Cdk5
association seems to be important for neurite outgrowth in vitro
and for the maintenance of proper neuronal morphology [14,45–
47]. It is widely accepted that Pak is a regulator of actin dynamics
in many cell types because it regulates LIM kinase (LIMK) and
cofilin phosphorylation [48], even if the precise mechanisms are
not yet understood. Some studies show that the modulation of
Pak1 by p35/Cdk5 and Rac1, could create a signaling complex
mechanism aimed at temporally control the activation of
downstream events regulating the LIMK- actin/cofilin dynamics
[37,45].
A similar extent of regeneration that we observed in our study
after Rac1 selective activation was found also in studies where
RhoA was inactivated in RGCs by C3 transferase treatment [18].
RhoA and Rac1 often display opposite effects in many aspects of
cell biology [6], and we cannot exclude that the mutants used in
this study could indirectly lead to RhoA inactivation. It will be
interesting to verify this hypothesis in further experiments.
The extent of regeneration we obtained is small, but we
manipulated only a single protein, while it is known that in order
to obtain a massive fast axonal growth multiple agents must be
administered and many proteins should be manipulated at the
same time [41]. The advantage of using the cell penetrating
proteins is that they display a pharmacological profile as shown by
the dose-dependent effect of Rac1L61F37A mutant on neuronal
survival.
Rac1 Selective Activation Prevented Axonal
Degeneration
Another finding of our study is that long-term treatments with
the Rac1L61F37A were able to delay the progressive axonal
degeneration as compared to undertreated control neurons. To
our knowledge, very few, mainly in vitro studies imply Rac1
disregulation in axonal degeneration [49,50]. One in vivo study
concerns the modifier of cell adhesion (MOCA), a presenilin
binding protein capable of activating Rac1. The loss of MOCA in
mice leads to axonal degeneration and causes sensorimotor
impairments by decreasing cofilin phosphorylation and altering
its upstream signaling partners LIMK and Pak [27]. Although
these studies are in accordance with our observations, the
possibility of using Rac1 selective activation in order to prevent
degeneration should be thoroughly verified in further experiments,
for instance by improving the way of administration of the Tat-
proteins.
Conclusions
Our study demonstrates the role of Rac1 in the modulation of
neuronal survival, dendrite morphology and axon remodeling and
suggests the importance of better defining the intracellular
signaling networks triggered by Rac1 small GTPase in neurons.
Moreover, it suggests that the modulation of selective Rac1-
dependent signaling pathways could be an effective strategy to
improve neuron survival, axonal regeneration or to prevent
degeneration in the CNS. Recent studies addressing issues
concerning the administration of Trojan fusion proteins directly
into the brain [51,52], suggest the realistic possibility of using our
Trojan fusion Rac1 mutants as a potential therapeutic approach to
modulate neuron survival and axonal regeneration in neurode-
generative diseases.
Supporting Information
Figure S1 The Brainbow 1.0 mouse as a tool to study
axonal regeneration of optic nerve after injury. In the
Brainbow 1.0 mouse retina only the RFP signal is normally
present. After intravitreal injection of AAV-Cre-GFP, a genetic
recombination occurs within a few days, allowing the combina-
torial expression of YFP and CFP. The RFP is concomitantly
deleted during the recombination. Given that the CFP signal was
negligible in the optic nerve we decided to show only the YFP. A
scheme of the experiment is shown in the upper panel: 2 days after
the AAV-Cre-GFP injection a crush lesion was performed. Rac1
mutants or vehicle were ivit injected. During the 15 days post-
injection, the recombination occurs only in surviving neurons.
Given that recombination occurs after axonal disconnection from
the target, the YFP signal will be found only in surviving neurons
and in newly formed axonal sprouts. This model allows a clear
distinction of the regenerating neurons from the old RFP positive
axonal remnants undergoing Wallerian degeneration. Examples of
the optic disc and of the optic nerve at the end of the experiment
are shown in the lower panels. Here a Rac1L61F37A treated
nerve is shown because in control nerves no regenerating axons
are present. Given that about the 75% of neurons recombine, the
regeneration is underestimated, but this model allows to analyze
the whole mounted nerve without need of staining or complex
handling. Moreover the whole mounted nerve can be directly
acquired by laser scanning microscopy and regeneration can be
assessed directly on the confocal stacks.
(TIF)
Figure S2 Scheme of the Tat-proteins and amino acid
sequence. A) Scheme of the recombinant protein mutants in
which all the mutations are indicated: an Histidine tail is followed
by a Tat trojan sequence and by the Rac1 protein isoform. The
Q61L point mutation tonically activates the protein, the N17
inactivate Rac1, whereas the mutations F37A and Y40C block the
interactions with some downstream Rac1 effectors. B) Complete
amino acid sequence of the different Rac1 isoforms, where the
Histidine tag (red), the Tat sequence (green) and the point
mutations (yellow) are highlighted.
(TIF)
Figure S3 Intracellular uptake of Rac1 mutant after
intravitreal injection. Representative confocal images of whole
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mounted retinas three days after vehicle (A–B) or Tat-Rac1
protein (C–D) injections showing immunoreactivity for the 6-
histidine tail of the recombinant protein (Histag, red), the neuronal
marker bIII-tubulin (green) and nuclei (DAPI, blue). A diffuse
immunoreactivity for Histag confirmed the successful injection
and uptake of the Tat-conjugated mutant. Scale bars 50 mm.
(TIF)
Figure S4 Recombinant proteins are detectable after 2
days from injection in normal retina. Retina sections were
immunostained by using anti-Histag antibodies at different time
points after a single ivit injection of Tat-proteins. A clear positivity
was found after 2 days (D to F) but the protein was undetectable at
4 days from the injection (G to I). bIII-tubulin staining (blue in the
right panels) confirms the neuronal uptake of the Tat-proteins.
GFAP (green) level is low and restricted to the upper layer because
retinal astrocytes are not activated. Scale bar 30 mm. GCL:
granule cell layer.
(TIF)
Figure S5 Increased positivity for PAK-p and ERK1/2-p
after Rac1L61F37A treatment. Representative images show-
ing retina sections immunostained by antibodies against the pan-
specific and the phosphorylated form of Pak, ERK1/2 and JNK.
Retinas were dissected and immunostained 3 days after optic
nerve crush and ivit treatment with either vehicle, or Rac1WT, or
L61F37A, or L61Y40C. Here we highlight some results relative to
the F37A treatment, as complementary of the images shown in
Fig.6. After F37A treatment we observed an increase of positivity
for ERK1/2-p and PAK-p not found neither in vehicle nor in WT
treatments. GCL: granule cell layer; IPL: inner plexiform layer;
INL inner nuclear layer. Scale bar 30 mm.
(TIF)
Figure S6 Rac1 selective activation increased ERK1/2-p
and PAK1-p in normal retina. Examples of retina sections 2
days after a single ivit injection of L61Y40C (A–B) or L61F37A
(E–F), without optic nerve crush. An untreated retina is shown as
control (C–D, G–H). The treatment with L61Y40C is able to
increase ERK1/2-p in non-neuronal cells, as shown by the lacking
of colocalization with MAP2. Here the GFAP colocalization is not
useful because in normal retina the glia is not activated as happens
after crush, so the GFAP level is very low and restricted to the
surface of the retina (as shown in F, green). The L61F37A is able
to increase the positivity of RGCs for PAK-p (E–F) respect to the
control (G–H). Scale bar 20 mm. GCL: granule cell layer.
(TIF)
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